Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Medical Hypotheses

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.mehy.2011.01.036PMID 21345596
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.

  2010cited by this paper
• Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention

  2010cited by this paper
• Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1.

  2010cited by this paper
• Drug‐Induced QT‐Interval Prolongation: Considerations for Clinicians

  2010cited by this paper
• Cardiac side-effects of cancer chemotherapy.

  2010cited by this paper
• Cardiovascular side-effects of modern cancer therapy.

  2010cited by this paper
• Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

  2010cited by this paper
• Cardiac toxicity from systemic cancer therapy: a comprehensive review.

  2010cited by this paper
• Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator–Activated Receptor γ

  2008cited by this paper
• Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion

  2008cited by this paper
• Specific components of prostanoid-signaling pathways are present in non-small cell lung cancer cells.

  2007cited by this paper
• Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis

  2007cited by this paper
• Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression.

  2006cited by this paper
• Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin.

  2006cited by this paper
• Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor.

  2005cited by this paper
• Pulmonary Prostacyclin Synthase Overexpression Chemoprevents Tobacco Smoke Lung Carcinogenesis in Mice

  2004cited by this paper
• Distinct functions of COX-1 and COX-2.

  2002cited by this paper
• Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer.

  2002cited by this paper
• Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth.

  2002cited by this paper
• Cyclooxygenase-2--10 years later.

  2002cited by this paper
• Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.

  2001cited by this paper
• Cardioprotective effects of beraprost sodium against experimental ischemia and reperfusion as compared with propranolol and diltiazem.

  1998cited by this paper
• Effect of beraprost sodium on changes in action potentials during hypoxia as compared with propranolol, diltiazem and glibenclamide in guinea-pig ventricular muscle.

  1994cited by this paper
• Endogenous prostacyclin preserves myocardial function and endothelium-derived nitric oxide formation in myocardial ischemia.

  1992cited by this paper
• Prostacyclin rather than endogenous nitric oxide is a tissue protective factor in myocardial ischemia.

  1992cited by this paper
• Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors.

  1989cited by this paper
• Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients.

  1988cited by this paper
• Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids.

  1988cited by this paper
• Protective actions of a stable prostacyclin analog in ischemia induced membrane damage in rat myocardium.

  1987cited by this paper
• On the late antiischaemic action of the stable PgI2 analogue: 7-oxo-PgI2-Na and its possible mode of action.

  1984cited by this paper
• Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size.

  1984cited by this paper
• Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation.

  1976cited by this paper

• Regulation of inflammation in cancer by dietary eicosanoids.

  2023cites this paper
• In silico homology modelling and identification of Tousled-like kinase 1 inhibitors for glioblastoma therapy via high throughput virtual screening protein-ligand docking

  2018cites this paper
• Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.

  2016cites this paper
• Iloprost prevents doxorubicin mediated human cardiac progenitor cell depletion.

  2014cites this paper
• Non-steroid anti-inflammatory drugs, prostaglandins, and cancer

  2013cites this paper
• Smooth muscle cell proliferation and endothelin pathway in pulmonary arterial hypertension : comparative effects of current and putative therapeutic agents

  2013cites this paper